Clinical trials: Glucagon
Schizophrenia, Prediabetic State
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and…
- Trial name
- HISTORI (NCT05193578)
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- Denmark
- Volunteers
- 154 people
- Sponsor
- Jan Frystyk
Type 2 Diabetes
Exercise and GLP-1 RA on Insulin Secretion
The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide, in patients with type 2…
- Trial name
- EXISECRET (NCT04383197)
- Testing
- Endurance exercise training, Semaglutide
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Copenhagen
Diabetes Mellitus, Type 2
A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects
The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of multiple oral doses of DBPR108 in healthy male subjects.
- Trial name
- NCT02163278
- Testing
- DBPR108
- Where
- Taiwan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Short Bowel Syndrome
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome
- Trial name
- NCT00673751
- Testing
- GLP-2
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Hyperglucagonemia, Obesity
Effects of Glucagon Administration on Energy Expenditure
The purpose of this study is to collect data to help researchers better understand the effects of glucagon on the amount of calories burned.
- Trial name
- GLEE (NCT02237053)
- Testing
- Glucagon, Octreotide, Insulin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Drug-specific Antibodies, Diabetes Mellitus
Evaluate the Immunogenicity of a Novel Glucagon Formulation
This study provides information on immunogenicity of Nasal Glucagon (AMG504-1) with regards to the potential development of treatment-emergent anti-glucagon antibodies.
- Trial name
- NCT01959334
- Testing
- Nasal Glucagon (NG), Glucagon IM
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
Obesity
Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion
The goal of this clinical trial is to evaluate the physiological effects of a WM Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage.
- Trial name
- NCT07097987
- Testing
- WM formula Group, Control group
- Where
- Taiwan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Pulmonary Aspiration
Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
The purpose of this study is to determine the type of gastric content and quantify the volume of liquid gastric contents using ultrasonography in patients on GLP-1 agonists that have presented for elective surgery and to…
- Trial name
- NCT05889637
- Testing
- Gastric ultrasound
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- The University of Texas Health Science Center, Houston
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
- Trial name
- NCT06500299
- Testing
- HDM1002 100 mg QD, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes
Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance
The study aims to evaluate the elimination and degradation of glucagon in patients with type 2 diabetes compared to matched healthy subjects.
- Trial name
- MCR Glucagon (NCT02475421)
- Testing
- Glucagon
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 1 Diabetes
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus
The purpose of this study is to identify the safest dose of very low dose glucagon to prevent hypoglycemia in patients with Type I diabetes who use insulin pumps and to measure the the amount of glucagon in the blood and see how…
- Trial name
- NCT00304538
- Testing
- very low dose (VLD) glucagon
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- DiObex
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Healthy
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.
- Trial name
- GLP-2ant (NCT06774807)
- Testing
- Saline infusion, Saline injection, 1nmol antagonist infusion
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Type 2 Diabetes Mellitus
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study is designed to evaluate the safety and tolerability of a range of single oral doses of LGD-6972 in healthy subjects. Additionally, the study will characterize the Pharmacokinetic profile in healthy subjects under fed…
- Trial name
- NCT01919684
- Testing
- LGD-6972
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ligand Pharmaceuticals
Type 2 Diabetes
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
In normal physiology, glucagon from pancreatic alpha cells plays an important role in maintaining glucose homeostasis via its regulatory effect on hepatic glucose production.
- Trial name
- NCT02792400
- Testing
- LY2403021, Standardised liquid meal, Linagliptin
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Familial Renal Glucosuria, Diabetes Mellitus
Human Solute Carrier Family 5 Member 2 (SLC5A2) Deficiency and the Glucagon-Incretin Axis
Sodium-glucose-cotransporter 2 (SGLT2) are a new type of oral antidiabetic drugs. SGLT2 inhibitors increase the urinary glucose excretion and thereby decrease blood glucose levels.
- Conditions
- Familial Renal Glucosuria, Diabetes Mellitus, Cardiovascular Diseases
- Trial name
- NCT03965000
- Testing
- Mixed-meal-tolerance-test
- Where
- Austria
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Healthy Volunteers Recruited From the General Population
Rapid Versus Slow Ingestion of Mixed Meal: Influence on Islet and Incretin Hormone Secretion in Healthy Volunteers
To test the influence of rapid versus slow ingestion of a mixed meal on insulin and incretin hormone secretion in healthy volunteers
- Trial name
- NCT01779622
- Testing
- Mixed meal
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lund University
Transfusion Dependent Beta Thalassemia
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia
Blood transfusion and iron-chelation therapy have prolonged and improved the quality of life in patients with β-thalassemia. The improvement was mainly due to the decrease in mortality from heart failure Such a treatment…
- Trial name
- NCT07370922
- Testing
- Dulaglutide 0.75Mg/0.5Ml Inj Pen, control group (insulin)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Type 1 Diabetes
Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals
The diabetes technology group at Imperial College have developed a bio-inspired artificial pancreas (BiAP) system which uses a control algorithm based on a mathematical model of beta-cell physiology.
- Trial name
- NCT02397265
- Testing
- Bi-hormonal closed loop pump, Standard opened loop pump, Insulin closed loop
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Imperial College London
Type 1 Diabetes Mellitus
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients
Primary Objective: To assess the tolerability and safety of SAR438544 after single ascending subcutaneous (SC) doses in healthy subjects and in type 1 diabetes mellitus (T1DM) patients.
- Trial name
- NCT02625636
- Testing
- SAR438544, r-glucagon
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi